Q-omics provides the consensus-scored C1QL3 profile across patient tissues and cancer cell-line models. C1QL3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C1QL3 is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, C1QL3 RNA expression shows 17,579 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KIRP, and UVM as cancer lineages where C1QL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1QL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1QL3 survival associations across molecular data types. C1QL3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1QL3 RNA expression–survival associations across cancer types. High C1QL3 expression shows unfavorable associations in ESCA, DLBC and UVM, but favorable associations in KIRC, KIRP and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C1QL3 RNA expression.
This table summarizes C1QL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for C1QL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1QL3 shows lower tumor expression in KIRP, KICH, LUSC, LUAD, UCEC and COAD. The KIRP box plot shows higher C1QL3 RNA expression in normal versus tumor tissue (log2 FC = −0.719, t-test p = .001).
This table shows molecular features associated with C1QL3 in patient tissues and cancer cell lines. In patient samples, C1QL3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C1QL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
